dr. bryce on the fda approval of rucaparib in brca-mutant mcrpc
Published 4 years ago • 190 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:15
dr. birrer on fda approval of rucaparib in ovarian cancer
-
2:46
dr. brufsky on the fda approval of olaparib in brca breast cancer
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
5:15
fda d.i.s.c.o.: rucaparib in ovarian cancer
-
1:08
dr. bryce on ongoing research in prostate cancer
-
3:56
parp inhibitors: activity in brca1 versus brca2 altered mcrpc
-
1:30
dr. agarwal on the safety profile of olaparib in hrr gene-mutant mcrpc
-
9:02
chemotherapy for brca-mutated prostate cancer
-
1:54
dr. o’malley on maintenance rucaparib in non-brca hrr-mutated in ovarian cancer
-
2:59
triton3 interim os results demonstrate superiority of rucaparib over docetaxel for mcrpc
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
1:10
dr. o'malley on fda approval of maintenance rucaparib in ovarian cancer
-
40:20
parp inhibitors treatment update - summit 2021
-
3:29
rucaparib boosts pfs in brca-mutated recurrent ovarian cancer
-
1:23
dr. bryce on treatment selection in nonmetastatic castration-resistant prostate cancer
-
6:32
metastatic prostate cancer: testing for brca mutations
-
4:10
new treatment for ovarian cancer - rubraca™ | cancer education & research institute
-
1:28
reducing the risk of prostate cancer | dana-farber cancer institute